Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The company will start a phase 2/3 trial of PF-08634404 in March.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
After a phase 3 push the livmoniplimab plan falters.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
The company discontinues one of its two KRAS G12D degraders.
